Comparing the clinical activity of Shankhpushpi (Convolvulus pluricaulis) and Selective Serotonin Reuptake Inhibitor in the management of PMDD(Premenstrual Dysphoric Disorder)

Comparison of manasroghara karma of Shankhpushpi (Convolvulus pluricaulis Chois.) with Selective Serotonin Reuptake Inhibitor (SSRI) in the management of Premenstrual Dysphoric Disorder (PMDD): A comparative open label randomised controlled clinical trial.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052722

Enrollment

Registered

2023-05-16

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F348- Other persistent mood [affective]disorders

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients fulfilling the diagnostic criteria for PMDD according to DSM 5

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women. 2. Patient on contr aceptives. 3. Patient suffering from any major systemic disease requiring significant care. 4. Patient with serious suicidal & Homicidal risk, 5. Patient having any kind of substance or alcohol dependence. 6. Patient suffering from any other psychiatric disorder

Design outcomes

Primary

Measure	Time frame
1)Relief in clinical sign and symptoms of PMDD. 2)Improvement in PSST scores by 25%.Timepoint: 2 months intervention and 2 months follow up	—

Secondary

Measure	Time frame
Fulfill the standard parameters of API and AFI for collected raw drug (shankhpushpi) and finished products (shankpushpi ghanavati)Timepoint: 2 months	—

Countries

India

Contacts

Public ContactDr Chavesh Mathnia

All India Institute Of Ayurveda

drmmeena@rediffmail.com9404049302

Outcome results